The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Molecular Control of Lymphatic Metastasis
Abstract
The metastatic spread of tumor cells is the most lethal aspect of cancer and often occurs via the lymphatic vasculature. Both experimental tumor models and human clinicopathologic data indicate that growth of lymphatic vessels (lymphangiogenesis) near solid tumors is often associated with lymph node metastasis. Changes in the adhesive properties of lymphatic endothelium near tumors may also facilitate metastatic spread via the lymphatics. Lymphangiogenic growth factors have been identified that promote formation of tumor lymphatics and metastatic spread of tumor cells to lymph nodes. These include the secreted glycoproteins vascular endothelial growth factor‐C (VEGF‐C) and VEGF‐D, which act via their cognate receptor tyrosine kinase VEGF receptor‐3 (VEGFR‐3) located on lymphatic endothelial cells. Other signaling molecules that have been reported to promote lymphangiogenesis and/or lymphatic metastasis in cancer include VEGF‐A, platelet‐derived growth factor‐BB, and hepatocyte growth factor. However, the quantitative contribution of these proteins to tumor lymphangiogenesis and lymphatic metastasis in different tumor types requires further investigation. In addition, chemokines are thought to play a role in attracting tumor cells and lymphatic vessels to each other. Moreover, it has recently been shown that lymphangiogenic growth factors secreted from a primary tumor can induce lymphangiogenesis in nearby lymph nodes, even before arrival of tumor cells, which may facilitate further metastasis. This article provides an overview of the molecular mechanisms that control lymphatic metastasis and discusses potential therapeutic approaches for inhibiting this process in human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis
Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N., & Yancopoulos, G. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81813-9 · Cited by 2,847
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275
Millauer, B., Wizigmann-Voos, S., Schnürch, H., Martinez, R., Møller, N. P. H., Risau, W., & Ullrich, A. (1993) · Cell · doi:10.1016/0092-8674(93)90573-9 · Cited by 1,927
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., & Detmar, M. (2001) · Nature Medicine · doi:10.1038/84643 · Cited by 1,733
Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., & Alitalo, K. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00359.x · Cited by 1,672
Cited by
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Lohela, M., Bry, M., Tammela, T., & Alitalo, K. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.012 · Cited by 738
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Saharinen, P., Eklund, L., Pulkki, K., Bono, P., & Alitalo, K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.015 · Cited by 478
Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D. A., Ramos, C., Garcia-Hernandez, A. A., & Falfan-Valencia, R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.010 · Cited by 373
The impact of VEGF on cancer metastasis and systemic disease
Yang, Y., & Cao, Y. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.011 · Cited by 286
Karnezis, T., Shayan, R., Caesar, C., Roufail, S., Harris, N. C., Ardipradja, K., Zhang, Y. F., Williams, S. P., Farnsworth, R. H., Chai, M. G., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.026 · Cited by 281
Self-citation
Metadata
- Authors
- Achen, M. G., & Stacker, S. A.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2008-05
- Volume
- 1131
- Issue
- 1
- Pages
- 225-234
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1969529130
- Cited by
- 260
- References
- 123
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Control of Lymphatic Metastasis. https://app.cochat.ai/papers/10.1196/annals.1413.020
- The paper
- Achen, M. G., & Stacker, S. A. (2008). Molecular Control of Lymphatic Metastasis. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1413.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.